open access

Vol 2, No 2 (2011)
Case report
Published online: 2011-07-15
Get Citation

The effectiveness of combination of rituximab–cyclophosphamide–dexamethasone in the treatment of Waldenstrom’s macroglobulinemia despite of the failure of several earlier lines of treatment

Anna Waszczuk-Gajda, Jadwiga Dwilewicz-Trojaczek, Piotr Boguradzki, Jolanta Wieczorek, Grzegorz Hensler, Małgorzata Paszkowska-Kowalewska, Bogna Ziarkiewicz-Wróblewska, Laretta Grabowska-Derlatka, Wiesław Wiktor Jędrzejczak
Hematologia 2011;2(2):209-213.

open access

Vol 2, No 2 (2011)
CASE REPORTS
Published online: 2011-07-15

Abstract

A 45-year-old man presented with diagnosis of Waldenstrom’s macroglobulinemia, International Prognostic Scoring System for Waldenström’s macroglobulinemia intermediate, is described. Between 2005 and 2008 he was treated with chlorambucil and prednisone then with fludarabine, and later with cyclofosfamid–vincristine–prednisone regimens but only temporary stabilization of disease was achieved. In 2008 the dynamic, histologically confirmed progression of the disease was observed. The high tumor burden and aggressive clinical features prompted the initiation of rituximab–dexamethasone–cyclophosphamide (RDC) therapy. The treatment course was uneventful and without toxicity. Following 6 courses of RDC a complete response (CR) was achieved in January 2009 and the patient remains in CR so far.
Hematologia 2011; 2, 2: 209–213

Abstract

A 45-year-old man presented with diagnosis of Waldenstrom’s macroglobulinemia, International Prognostic Scoring System for Waldenström’s macroglobulinemia intermediate, is described. Between 2005 and 2008 he was treated with chlorambucil and prednisone then with fludarabine, and later with cyclofosfamid–vincristine–prednisone regimens but only temporary stabilization of disease was achieved. In 2008 the dynamic, histologically confirmed progression of the disease was observed. The high tumor burden and aggressive clinical features prompted the initiation of rituximab–dexamethasone–cyclophosphamide (RDC) therapy. The treatment course was uneventful and without toxicity. Following 6 courses of RDC a complete response (CR) was achieved in January 2009 and the patient remains in CR so far.
Hematologia 2011; 2, 2: 209–213
Get Citation

Keywords

Waldenstrom’s macroglobulinemia; rituximab; rituximab–dexamethasone–cyclophosphamide (RDC) schedule

About this article
Title

The effectiveness of combination of rituximab–cyclophosphamide–dexamethasone in the treatment of Waldenstrom’s macroglobulinemia despite of the failure of several earlier lines of treatment

Journal

Hematology in Clinical Practice

Issue

Vol 2, No 2 (2011)

Article type

Case report

Pages

209-213

Published online

2011-07-15

Bibliographic record

Hematologia 2011;2(2):209-213.

Keywords

Waldenstrom’s macroglobulinemia
rituximab
rituximab–dexamethasone–cyclophosphamide (RDC) schedule

Authors

Anna Waszczuk-Gajda
Jadwiga Dwilewicz-Trojaczek
Piotr Boguradzki
Jolanta Wieczorek
Grzegorz Hensler
Małgorzata Paszkowska-Kowalewska
Bogna Ziarkiewicz-Wróblewska
Laretta Grabowska-Derlatka
Wiesław Wiktor Jędrzejczak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.